BioSpace News Archive

aTyr Pharma, Inc. today announced that the company will present two posters at the Keystone Symposia on Myeloid Cell Diversity: From Fundamental Biology to Disease States, which is being held January 28 – 31, 2024, in Banff, Alberta, Canada.

Corcept Therapeutics Incorporated today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, and join the company’s Executive Team.

OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its participation as an exhibitor at the 15th Annual SCOPE Summit for Clinical Ops Executive (the “SCOPE Summit”) being held February 11-14, 2024 in Orlando, FL.

Longeveron Inc. today announces it received a notice of patent allowance from the United States Patent and Trademark Office (PTO) for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product Lomecel-B TM.

Ractigen Therapeutics announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University.

Crystal Bio, an innovative spinout division of Crystal Pharmatech, is excited to announce Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer (CSO).

IceCure Medical Ltd. today announced the Company is exhibiting and conducting hands-on ProSense® demonstrations at the Society of Interventional Oncology’s (“SIO”) Annual Scientific Meeting which takes place from January 25-29, 2024 in Long Beach, California.

Building upon its flagship Endosafe ® cartridge technology, Charles River Laboratories International, Inc. (NYSE: CRL) has advanced this innovation one step further and combined it with their recombinant cascade reagent (rCR) to launch the Endosafe ® Trillium™ rCR cartridge offering.

Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration.

Tharimmune, Inc. (NASDAQ:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announces initiation of a Phase 1 trial with TH104, utilizing a proprietary oral thin film.